Nelmastobart plus docetaxel for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, nelmastobart, combined with the chemotherapy docetaxel, for people with advanced non-small cell lung cancer that has a high level of a protein called BTN1A1. It is for patients who have already tried other treatments and are looking for a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIb, IIIc, or IV) non-small cell lung cancer that has come back or spread.
- Your tumor has a high level of a protein called BTN1A1 (a score of 50% or higher).
- You have already had at least one type of chemotherapy or immunotherapy, and if you have a specific gene mutation, also a targeted therapy.
- You are able to take care of yourself and are up and about more than half of the day (ECOG 0-1).
- Your major organs (liver, kidneys, heart, bone marrow) are working well enough.
- You are willing to provide a sample of your stored tumor tissue for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug Benmelstobart after surgery can help prevent return of a specific type of lung cancer. It is for people with stage IB, grade 3 (poorly differentiated) lung adenocarcinoma that has been completely removed.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This study tests a new drug called ABBV-1480 combined with chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see if it works as well as or better than the current standard treatment, pembrolizumab (also known as Keytruda) with chemotherapy.
This trial tests whether adding the drug plinabulin to the standard chemotherapy docetaxel helps people with advanced non-squamous non-small cell lung cancer (NSCLC) whose cancer has progressed after prior treatment with immunotherapy and chemotherapy. The study aims to see if the combination works better than docetaxel alone in slowing cancer growth.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.